Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Patient Guides COVID19 1000x250

Adaptations to aggressive lymphoma (DLBCL, MCL, TCL) management

High priority

Your appointment may be a high priority if:

  • You are due to undergo curative treatment for aggressive lymphoma. In these cases, your chemotherapy schedule might be altered to reduce the number of clinic visits required, without affecting the curative potential of the treatment. Your doctor may also decide to change your planned regimen to a less myelosuppressive one. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
  • You have been diagnosed with relapsed diffuse large B-cell lymphoma (DLBCL) and are scheduled to receive high-dose chemotherapy with autologous stem cell support
  • You are receiving treatment as part of a clinical trial
  • You have refractory DLBCL and are scheduled to receive CAR-T cell therapy

Medium priority

Your appointment may be a medium priority if:

  • shutterstock_1107100178
    You are scheduled to receive non-curative treatment, such as systemic therapy for relapsed aggressive lymphoma that is not eligible for autologous stem cell support. In these cases, your treatment may be modified to reduce clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia.  Drugs that suppress T cells (e.g. bendamustine) will be avoided
  • You are due to receive prophylactic treatment with high-dose methotrexate, high-dose cytarabine and/or intrathecal methotrexate. These treatments may be cancelled during the COVID-19 pandemic
  • You are due to receive palliative radiotherapy or consolidation radiotherapy. These treatments may be delayed

High priority

Your appointment may be a high priority if:

  • You are due to undergo first-line treatment for mantle cell lymphoma (MCL). In these cases, your chemotherapy schedule might be altered to reduce the number of clinic visits required. You may also receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
  • You are receiving treatment as part of a clinical trial

Medium priority

Your appointment may be a medium priority if:

  • You are scheduled to receive systemic therapy for relapsed MCL. In these cases, your treatment may be modified to reduce clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia, and drugs that suppress T cells (e.g. bendamustine) will be avoided
  • shutterstock_218458957
    You are scheduled to receive high-dose chemotherapy with autologous stem cell support as consolidation therapy. This treatment may be delayed
  • You are due to receive maintenance therapy with rituximab. This treatment may be delayed
  • You are due to receive palliative radiotherapy. This treatment may be delayed

High priority

Your appointment may be a high priority if:

  • You are due to undergo first-line treatment for aggressive T-cell lymphoma. In these cases, your chemotherapy schedule might be altered to reduce the number of clinic visits required. You may also receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
  • You are receiving treatment as part of a clinical trial

Medium priority

Your appointment may be a medium priority if:

  • shutterstock_1726918912
    You are scheduled to receive systemic therapy for relapsed aggressive T-cell lymphoma. In these cases, your treatment may be modified to reduce clinic visits. You may receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia, and drugs that suppress T cells (e.g. bendamustine) will be avoided
  • You are scheduled to receive high-dose chemotherapy with autologous stem cell support as consolidation therapy. This treatment may be delayed
  • You are due to receive palliative radiotherapy. This treatment may be delayed

 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings